Las Vegas, NV / Syndication Cloud / January 23, 2026 / ContrastConnect The American College of Radiology (ACR) and the ...

In a new pilot feasibility study, researchers from Mayo Clinic, the University of Washington School of Medicine, the ...

Researchers from the University of Washington School of Medicine in Seattle, Mayo Clinic in Rochester, Minn., the University ...

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane ...

BR55 was safe and highly accurate (>95%) at marking VEGFR2 expression in patients with breast, ovarian and thyroid cancer, as well as Crohn disease. The Food and Drug Administration (FDA) has granted ...

ORLANDO, FL — In the AVERT trial of close to 600 patients who underwent coronary angiography and were at high risk of contrast-induced acute kidney injury (AKI), the studied device successfully ...

Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...

Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics and safety ...

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

A research team from IOCB Prague, working in collaboration with the University of Tübingen, Germany, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can ...